Breaking News, Collaborations & Alliances

Enleofen Bio Develops First-In-Class Fibrosis Treatment With Support From Abzena

The target aims to transform the treatment of patients suffering from various types of fibrosis

Abzena plc, a technology and service provider for the development and manufacturing of biopharmaceutical products, is collaborating with Enleofen Bio to develop antibody therapeutics for the treatment of fibrotic human diseases.   Enleofen Bio discovered that inhibiting Interleukin 11 (IL11) prevents fibrosis through a wide range of pathways. They have developed various IL11 inhibitors, and their development program is now being advanced with the use of Abzena’s Composite CHO cell line t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters